- |||||||||| MBS309 / Beijing Mabworks Biotech
Preclinical characterization of MBS309, a conditionally active PD-1-dependent IL-2 mutation with significantly superior anti-tumor efficacy with safety (Section 4) - Mar 5, 2024 - Abstract #AACR2024AACR_6989;
In our in vivo tumor murine models, 1mg/kg MBS309 showed much better suppression effect in MC38/hPD-L1 tumor than 1mg/kg RG6279 analog and Pembrolizumab (1mg/kg) combination with wild type IL-2 (0.1mg/kg); And MBS309 at the dosage of 5mg/kg can significantly inhibit tumor growth in PD-1 resistant Pan-02 xenograft models without any side-effects observed, while RG6279 analog at the dosage of 5mg/kg induced severe body reduction of the mice and resulted in 80% (4/5) mice death after two dosages...20mg/kg of MBS309 was well tolerated in mouse, while 10mg/kg of RG6279 analog or PF-07209960 analog show severe toxicity and resulted in death of all the mice...And it shows much higher anti-tumor effect compared to anti-PD-1/-L1 antibodies alone in both PD-1 sensitive and resistant tumor models. MBS309 has demonstrated a favorable safety profile and highly anti-tumor activities in vivo, which has the potential to supporting its clinical development for the treatment of cancer.
- |||||||||| eciskafusp alfa (RG6279) / Roche, Tecentriq (atezolizumab) / Roche
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 22, 2023
P1, N=256, Recruiting,
MBS309 has demonstrated a favorable safety profile and highly anti-tumor activities in vivo, which has the potential to supporting its clinical development for the treatment of cancer. Phase classification: P1a/1b --> P1 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Nov 2026
- |||||||||| eciskafusp alfa (RG6279) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Tumor mutational burden, IO biomarker, Metastases: A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 25, 2023
P1a/1b, N=348, Recruiting,
Phase classification: P1a/1b --> P1 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Nov 2026 Trial completion date: Jun 2027 --> Nov 2026 | Trial primary completion date: Mar 2027 --> May 2026
- |||||||||| eciskafusp alfa (RG6279) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Tumor mutational burden, IO biomarker, Metastases: A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 7, 2022
P1a/1b, N=440, Recruiting,
Trial completion date: Jun 2027 --> Nov 2026 | Trial primary completion date: Mar 2027 --> May 2026 Trial completion date: Aug 2024 --> Jun 2027 | Trial primary completion date: Apr 2024 --> Mar 2027
- |||||||||| RG6279 / Roche
[VIRTUAL] PD1-IL2v: A next generation, PD-1-targeted cytokine (Channel 02) - Mar 13, 2021 - Abstract #AACR2021AACR_4171;
High-affinity PD-1 binding allows IL2v to effectively expand tumor-antigen specific T-cells, and to differentiate those cells towards better, non-dysfunctional immune effectors, to much higher levels vs. anti-PD-1/-L1 antibodies alone or in combination with either tolerable doses of standard IL-2 or with a non-PD-1-targeted 2nd generation IL-2Rbg agonist currently in clinical development, and thus mediate significantly superior anti-tumor efficacy at well tolerated drug doses. PD1-IL2v is currently being tested in a Ph1 clinical trial.
- |||||||||| eciskafusp alfa (RG6279) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 7, 2020
P1a/1b, N=440, Recruiting,
These preclinical data support the combination of SQZ-PBMC with FAP-IL2v or PD1-IL2v targeted immunocytokine as promising cancer immunotherapies. Not yet recruiting --> Recruiting
- |||||||||| eciskafusp alfa (RG6279) / Roche, Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 11, 2020
P1a/1b, N=440, Not yet recruiting,
|
